Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells and reversed diabetes in a preclinical study. The new approach, which ...

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...

Noninvasive monitoring methods, such as enterography and ultrasound, are becoming increasingly recognized as essential tools ...

The world-wide pandemic involving SARS-CoV2 in which high infectivity and pathogenesis necessitated the critical need for rapid and accurate preclinical ...

Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug ...

An international team led by researchers at the University of Toronto has found a compound in ginger, called furanodienone ...

Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic ...

CJRB-201', a proprietary strain of Faecalibacterium with potent its anti-inflammatory effects, has demonstrated the strongest ...

Selectively binds and activates CD8 Treg; does not activate cells that express only one target, including other ICOS-expressing immune cells Extends survival and decreases disease score in a ...